A New Marijuana Medicine Gets DEA Scheduling, but It's Not All Good News

A New Marijuana Medicine Gets DEA Scheduling, but It's Not All Good News


This week, the DEA finally announced that it's labelingSyndros as a Schedule II drug, and while that scheduling clears the way for Insys Therapeutics to begin marketing it, the DEA's decision fell short of the Schedule III rating that investors really wanted. Syndros is a liquid formulation of the THC drug Marinol, a medicine that's been used to treat anorexia in AIDS patients and chemotherapy-induced nausea and vomiting since the 1980s.



from Biotech News